The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 343:682-688 September 7, 2000 Number 10
NextNext

Transdermal Testosterone Treatment in Women with Impaired Sexual Function after Oophorectomy
Jan L. Shifren, M.D., Glenn D. Braunstein, M.D., James A. Simon, M.D., Peter R. Casson, M.D., John E. Buster, M.D., Geoffrey P. Redmond, M.D., Regula E. Burki, M.D., Elizabeth S. Ginsburg, M.D., Raymond C. Rosen, Ph.D., Sandra R. Leiblum, Ph.D., Kim E. Caramelli, M.S., Norman A. Mazer, M.D., Ph.D., Kirtley P. Jones, M.D., and Claire A. Daugherty, M.S.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Guzick, D. S.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause.

Methods Seventy-five women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day orally) and, in random order, placebo, 150 µg of testosterone, and 300 µg of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone.

Results The mean (±SD) serum free testosterone concentration increased from 1.2±0.8 pg per milliliter (4.2±2.8 pmol per liter) during placebo treatment to 3.9±2.4 pg per milliliter (13.5±8.3 pmol per liter) and 5.9±4.8 pg per milliliter (20.5±16.6 pmol per liter) during treatment with 150 and 300 µg of testosterone per day, respectively (normal range, 1.3 to 6.8 pg per milliliter [4.5 to 23.6 pmol per liter]). Despite an appreciable placebo response, the higher testosterone dose resulted in further increases in scores for frequency of sexual activity and pleasure–orgasm in the Brief Index of Sexual Functioning for Women (P=0.03 for both comparisons with placebo). At the higher dose, the percentages of women who had sexual fantasies, masturbated, or engaged in sexual intercourse at least once a week increased two to three times from base line. The positive-well-being, depressed-mood, and composite scores of the Psychological General Well-Being Index also improved at the higher dose (P=0.04, P=0.03, and P=0.04, respectively, for the comparison with placebo), but the scores on the telephone-based diary did not increase significantly.

Conclusions In women who have undergone oophorectomy and hysterectomy, transdermal testosterone improves sexual function and psychological well-being.


Source Information

From the Vincent Memorial Obstetrics and Gynecology Service, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston (J.L.S.); the Department of Medicine, Cedars–Sinai Medical Center, Los Angeles (G.D.B.); Women's Health Research Center, Laurel, Md. (J.A.S.); the Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston (P.R.C., J.E.B.); the Foundation for Developmental Endocrinology, Cleveland (G.P.R.); Salt Lake City (R.E.B.); the Center for Reproductive Medicine, Brigham and Women's Hospital, Boston (E.S.G.); the Department of Psychiatry, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, Piscataway (R.C.R., S.R.L.); and the Department of Clinical Research, Watson Laboratories–Utah, Salt Lake City (K.E.C., N.A.M.). Other authors were Kirtley P. Jones, M.D. (Department of Obstetrics and Gynecology, University of Utah Medical Center, Salt Lake City), and Claire A. Daugherty, M.S. (Anesta Corporation, Salt Lake City).

Address reprint requests to Dr. Shifren at Vincent Memorial Obstetrics and Gynecology Service, VBK-113, Massachusetts General Hospital, Boston MA 02114, or at janshifren{at}hotmail.com.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.